国产长春瑞滨联合卡铂治疗晚期非小细胞肺癌的临床研究  

Combination chemotheraphy of navelbine and arboplatin in treatment of non-small cell lung cancer

作　　者：范春香[1] 

机构地区：[1]河南省商丘市第一人民医院肿瘤科,476100

出　　处：《中国实用医刊》2010年第17期44-45,共2页Chinese Journal of Practical Medicine

摘　　要：目的 观察国产长春瑞滨(NVB)联合卡铂(CBP)治疗非小细胞肺癌(NSCLC)的疗效和毒性反应.方法 NVB 25mg/m2 静脉滴注第1、8天, CBP 300 mg/m2第1天,21～28 d为1个周期,完成2～6个周期.结果 45例患者中完全缓解(CR)5例,部分缓解(PR)119例,稳定(SD)10例,进展(PD)11例,总有效率(CR+PR)为53.3%.NVB主要不良反应为白细胞下降,其中Ⅲ、Ⅳ度为60%.结论 NVB加CBP方案可以作为NSCLC患者较理想的治疗方案,NVB加CBP方案具有较好的疗效和耐受性,可提高患者的生活质量.Objective To observe the efficacy and toxicity combined chemotherapy of NVB and CBP in treatment of non-small cell lung cancer(NSCLC).Methods NVB 25 mg/m2 iv. for day 1and 8,CBP 300 mg/m2 for day 1,the treatment was recycled every 21-28 days and finished 2-6 recycles. Results Complete response was achieved in 5 cases, partial response in 19 cases,stable in 10 cases,progression in 11 cases.The overall response rate was 53.3%.Leukopenia which was the most frequent toxicity were present in 73.3%, and the grades 3,grade 4 leukopnia were present in 60%.Conclusions Combination chemotherapy of NVB and CBP is well tolerated and effective in the treatment of NSCLC and can improve quality of life(QOL).

关 键 词：盖诺 卡铂 非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤]